Sentence: Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['paclitaxel', 'sorafenib'], 'is_context_needed': True}]